Please click here to access the ELIQUIS Patient Information Leaflet.
BD = Twice Daily INR = International Normalised Ratio ISTH = International Society on Thrombosis and Haemostasis LMWH = Low Molecular Weight Heparin NVAF = Non-Valvular Atrial Fibrillation
*ELIQUIS should be used with caution in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp.1 ELIQUIS is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp.1 See Summary of Product Characteristics for warnings and precautions in use and other important safety information.
†The ARISTOTLE clinical trial was a randomised, double-blind, double-dummy non-inferiority trial in 18,201 patients. Stroke / systemic embolism was the primary efficacy endpoint and major bleeding was the primary safety endpoint. The primary safety outcome was major bleeding, according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH). Pre-specified hierarchical sequential testing was performed first on stroke / systemic embolism (primary efficacy endpoint) for non-inferiority, then for superiority, then on major bleeding and, finally, on death from any cause (secondary endpoint).2
‡ ELIQUIS is not recommended for patients with creatinine clearance <15 ml/min, or in patients undergoing dialysis.1
ELIQUIS® (apixaban) Summary of Product Characteristics.
Granger CB et al. N Engl J Med 2011; 365: 981–992.
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.
All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.
Date of preparation: February 2020